Fusion Protein Purification Patents: Leaders & White Space 2026
Fusion protein purification patents: who holds the claim space and where it is still open
24.9% concentration at the top. The five most active assignees account for 118 of 473 records in scope — a leadership cluster, not a monopoly, with room below it. Filings peaked at 34 in 2017. By the last complete window, 2021 to 2024, volume held roughly steady — 14 down to 13 records, a -7% move that is closer to a plateau than a decline. Treat 2025 and 2026 figures as still filling in given publication lag.
- 1BRISTOL MYERS SQUIBB CO29
- 2NOVARTIS VACCINES23
- 3GLAXOSMITHKLINE BIOLOGICALS SA22
- 4NAT RES COUNCIL OF CANADA22
- 5AMUNIX PHARMACEUTICALS INC22
See the full fusion protein manufacturing — fusion-protein purification patent landscape analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on fusion-protein purification patents
Who are the leading patent holders in fusion-protein purification?
The ranked leader in this dataset holds 29 of the 473 records in scope, with the top five assignees together holding 118 records (24.9%) and the top ten holding 203 (42.9%). That leaves the majority of records spread across a long tail of assignees filing at low volume. Reviewing the leader’s full portfolio, not just its count, is necessary before assuming a blocking position — record count alone does not tell you claim scope.
Is fusion-protein purification patent filing growing or shrinking?
Filing peaked at 34 records in 2017 and has since settled to a lower, fairly stable level. Comparing 2021 (14 records) to 2024 (13 records) — the last years complete enough to compare fairly — shows a -7% change, which reads as a plateau rather than a genuine decline. Data from 2025 onward is still incomplete because publication lags filing by roughly 18 months, so recent years will look artificially low for some time yet.
Which patent classes matter most for fusion-protein purification claims?
C07K (peptides and proteins) appears in 96.4% of the 473 records and C12N (microorganisms and genetic engineering) in 84.6%, showing that purification claims are almost always filed alongside construct or expression claims rather than standing alone. A61K medicinal-preparation classes cover 63.8% of records and C12P fermentation and enzymatic synthesis covers 51.0%. A drafter targeting pure purification-process claims should still expect to search and cite across all of these classes.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Fusion Protein Manufacturing — Fusion-Protein Purification Patent Landscape covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.